LifeVantage (NASDAQ:LFVN) Earns Buy Rating from Analysts at Lake Street Capital

Lake Street Capital started coverage on shares of LifeVantage (NASDAQ:LFVN) in a research note released on Thursday morning, Marketbeat reports. The brokerage issued a buy rating and a $26.00 price objective on the stock.

LifeVantage Trading Down 2.1 %

Shares of NASDAQ:LFVN opened at $17.36 on Thursday. The company has a market cap of $217.43 million, a price-to-earnings ratio of 54.25 and a beta of 0.87. LifeVantage has a 12 month low of $5.22 and a 12 month high of $18.41. The company has a 50-day moving average price of $13.99 and a 200-day moving average price of $10.32.

LifeVantage (NASDAQ:LFVN) last released its quarterly earnings data on Tuesday, October 29th. The company reported $0.15 earnings per share for the quarter, hitting the consensus estimate of $0.15. LifeVantage had a return on equity of 29.24% and a net margin of 2.11%. The business had revenue of $47.21 million during the quarter.

LifeVantage Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, December 16th. Shareholders of record on Monday, December 2nd were issued a $0.04 dividend. The ex-dividend date was Monday, December 2nd. This represents a $0.16 annualized dividend and a yield of 0.92%. LifeVantage’s dividend payout ratio (DPR) is presently 50.00%.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Renaissance Technologies LLC boosted its position in shares of LifeVantage by 2.1% during the second quarter. Renaissance Technologies LLC now owns 855,118 shares of the company’s stock valued at $5,490,000 after purchasing an additional 17,300 shares in the last quarter. Capital Management Corp VA purchased a new position in LifeVantage during the third quarter valued at $5,073,000. HighTower Advisors LLC bought a new stake in shares of LifeVantage during the 3rd quarter valued at $638,000. Barclays PLC grew its position in shares of LifeVantage by 38.2% in the 3rd quarter. Barclays PLC now owns 41,966 shares of the company’s stock worth $507,000 after buying an additional 11,608 shares during the period. Finally, Ritholtz Wealth Management lifted its position in LifeVantage by 62.0% during the 3rd quarter. Ritholtz Wealth Management now owns 28,666 shares of the company’s stock valued at $346,000 after acquiring an additional 10,974 shares during the period. Hedge funds and other institutional investors own 35.32% of the company’s stock.

About LifeVantage

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix.